Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Breakthrough In Two Pages: FDA Offers Preliminary Advice

This article was originally published in The Pink Sheet Daily

Executive Summary

Agency now allows sponsors of potential breakthrough therapies to request preliminary advice, but sponsors may not necessarily want to use it.

You may also be interested in...



Breakthrough Denial Doesn't Mean US FDA Won't Bring Full Resources To Application

Agency staff discuss how they offer early development advice to sponsors before a breakthrough decision is made and reassure them if the status is denied.

FDA's Breakthrough Workload Will Be Eased By Hiring Reviewers With PDUFA VI Funds

User fees won't support dedicated staff, but rather FTEs that will work on the popular program as needed.

FDA's Breakthrough Bar May Be Set Too Low, Jenkins Says

Office of New Drugs Director recommends that EMA be careful how its sets the bar for its similar PRIME program to ensure it remains meaningful.

Related Content

Topics

UsernamePublicRestriction

Register

PS079244

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel